Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550197/
https://ncbi.nlm.nih.gov/pubmed/32820334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa496
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados